Kantar Health Blog

  • The Evolving Use of White Bagging in Oncology

    by User Not Found | Mar 28, 2014
    User Not Found
    Channel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers. Today, buy and bill’ is the primary method of distribution of IV oncology drugs, whereby oncology practices typically purchase these drugs from specialty distributors/group purchasing organizations (GPOs), which are then billed to payers under the medical benefit.
    Continue Reading > | Go comment! | Share
  • User Not Found
    Oncology Conference Insight: ASCO 2013 --- One of the hottest presentations this year is the results from a German cooperative group-sponsored FIRE-3 study (n=592), comparing first-line FOLFIRI in combination with low-dose (5 mg/kg every two weeks) Avastin (bevacizumab, Roche/Genentech) or standard dose Erbitux (cetuximab, Bristol Myers-Squibb, Eli Lilly, Merck KGaA) in metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.
    Continue Reading > | Go comment! | Share
  • User Not Found
    There has been a fair amount of talk lately about the impact of payment reductions for cancer care services by 2%, and a reduction in reimbursement for buy and bill cancer drugs from ASP + 6% to ASP +4.3. So what is the impact of sequestration on oncology – is it a practice catastrophe, or just a reduction in profits?
    Continue Reading > | Go comment! | Share
  • User Not Found
    Pricing a drug is a hugely important aspect of pre-launch and launch planning as it can directly influence market share. Forecasting the dollar value of an oncology drug presents many challenges and caveats and takes into account price, duration of therapy, the eligible population, and market share of the eligible population.
    Continue Reading > | Go comment! | Share
  • User Not Found
    Most practices have weathered the storm of declining drug reimbursement. Patient volumes remain strong and reimbursement appears to be stable or positive. Practices generally report slow growth toward expansion and ongoing efficiency improvements. However, options for service diversification appear to be narrowing, with large practices likely to have added services requiring capital investment already. Overall, minor modifications to practice operations continue as practices actively explore new ways to remain competitive.
    Continue Reading > | Go comment! | Share
Page